2020年 · 第100卷第13期

Since the outbreak of novel coronavirus, the number of infected cases has risen rapidly. With the development of the epidemic, cases have been reported all over the country and even abroad^[1,2,3,4]。 Timely diagnosis of acute, severe and suspected patients requires rapid and effective methods, and 2019 novel coronavirus (2019-nCoV) nucleic acid detection provides direct evidence for diagnosis^[5,6]。 In the process of nucleic acid detection, because the infection route and pathogenicity of pathogens have not been fully clarified, the staff have a greater risk of infection. In addition, because the gene structure of 2019-nCoV is quite different from that of general RNA, the testing process, testing quality and biosafety all need to be effectively standardized. This consensus was compiled on the basis of referring to relevant documents of the National Health Commission, consulting literature, and consulting relevant experts in heavily affected areas, so as to put forward guiding suggestions for laboratory testing. This consensus applies to all laboratories engaged in nucleic acid testing for 2019-nCoV.

focused ultrasound ablation surgery (FUAS) is a non-invasive local thermal ablation technology, which is an original and leading treatment technology in China^[1,2,3]。 FUAS was first used clinically in China. Since 1997, after years of clinical research and practice, this technology has become increasingly mature and widely used in the treatment of various solid tumors and benign diseases of some organs. Based on the evidence from clinical research and clinical practice, and after extensive discussion, the following consensus has been formed.